Treatable traits in the European U-BIOPRED adult asthma cohorts

Andrew J Simpson^{1

2}, Pieter-Paul Hekking³, Dominick E Shaw⁴, Louise J Fleming^{5

6}, Graham Roberts⁷, John H Riley⁸, Stewart Bates⁸, Ana R Sousa⁸, Aruna T Bansal⁹, Ioannis Pandis¹⁰, Kai Sun¹⁰, Per S Bakke¹¹, Massimo Caruso¹², Barbro Dahlén¹³, Sven-Erik Dahlén¹³, Ildiko Horvath¹⁴, Norbert Krug¹⁵, Paolo Montuschi¹⁶, Thomas Sandstrom¹⁷, Florian Singer¹⁸, Ian M Adcock^{5

6}, Scott S Wagers¹⁹, Ratko Djukanovic⁷, Kian Fan Chung^{5

6}, Peter J Sterk³, Stephen J Fowler¹; U-BIOPRED Study Group

Collaborators, Affiliations

Collaborators

U-BIOPRED Study Group:
H Ahmed, C Auffray, F Baribaud, E H Bel, J Bigler, H Bisgaard, M J Boedigheimer, K Bønnelykke, J Brandsma, P Brinkman, E Bucchioni, D Burg, A Bush, A Chaiboonchoe, P Chanez, C H Compton, J Corfield, A D'Amico, B De Meulder, V J Erpenbeck, D Erzen, K Fichtner, N Fitch, L J Fleming, E Formaggio, U Frey, M Gahlemann, T Geiser, V Goss, Y Guo, S Hashimoto, J Haughney, G Hedlin, P W Hekking, T Higenbottam, J M Hohlfeld, C Holweg, I Horváth, P Howarth, A J James, R Knowles, A J Knox, D Lefaudeux, M J Loza, R Lutter, A Manta, S Masefield, J G Matthews, A Mazein, A Meiser, R J M Middelveld, M Miralpeix, N Mores, C S Murray, J Musial, D Myles, L Pahus, S Pavlidis, A Postle, P Powel, G Praticò, M Puig Valls, N Rao, A Roberts, G Roberts, A Rowe, T Sandström, J P R Schofield, W Seibold, A Selby, R Sigmund, P J Skipp, B Thornton, W M van Aalderen, M van Geest, J Vestbo, N H Vissing, A H Wagener, Z Weiszhart, C E Wheelock, S J Wilson

Affiliations

¹ University of Manchester, and Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
² Department of Sport, Health and Exercise Science, School of Life Sciences, The University of Hull, Hull, UK.
³ Respiratory Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
⁴ Respiratory Research Unit, University of Nottingham, Nottingham, UK.
⁵ National Heart and Lung Institute, Imperial College, London, UK.
⁶ Royal Brompton and Harefield NHS Trust, London, UK.
⁷ NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK.
⁸ Respiratory Therapeutic Unit, GSK, London, UK.
⁹ Acclarogen Ltd, St John's Innovation Centre, Cambridge, UK.
¹⁰ Data Science Institute, Imperial College, London, UK.
¹¹ Department of Clinical Science, University of Bergen, Bergen, Norway.
¹² Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
¹³ Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.
¹⁴ Department of Pulmonology, Semmelweis University, Budapest, Hungary.
¹⁵ Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
¹⁶ Università Cattolica del Sacro Cuore, Milan, Italy.
¹⁷ Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
¹⁸ Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
¹⁹ BioSci Consulting, Maasmechelen, Belgium.

PMID: 30307629
PMCID: PMC6587719
DOI: 10.1111/all.13629

Treatable traits in the European U-BIOPRED adult asthma cohorts

Andrew J Simpson et al. Allergy. 2019 Feb.

. 2019 Feb;74(2):406-411.

doi: 10.1111/all.13629. Epub 2018 Nov 12.

Authors

Collaborators

U-BIOPRED Study Group:
H Ahmed, C Auffray, F Baribaud, E H Bel, J Bigler, H Bisgaard, M J Boedigheimer, K Bønnelykke, J Brandsma, P Brinkman, E Bucchioni, D Burg, A Bush, A Chaiboonchoe, P Chanez, C H Compton, J Corfield, A D'Amico, B De Meulder, V J Erpenbeck, D Erzen, K Fichtner, N Fitch, L J Fleming, E Formaggio, U Frey, M Gahlemann, T Geiser, V Goss, Y Guo, S Hashimoto, J Haughney, G Hedlin, P W Hekking, T Higenbottam, J M Hohlfeld, C Holweg, I Horváth, P Howarth, A J James, R Knowles, A J Knox, D Lefaudeux, M J Loza, R Lutter, A Manta, S Masefield, J G Matthews, A Mazein, A Meiser, R J M Middelveld, M Miralpeix, N Mores, C S Murray, J Musial, D Myles, L Pahus, S Pavlidis, A Postle, P Powel, G Praticò, M Puig Valls, N Rao, A Roberts, G Roberts, A Rowe, T Sandström, J P R Schofield, W Seibold, A Selby, R Sigmund, P J Skipp, B Thornton, W M van Aalderen, M van Geest, J Vestbo, N H Vissing, A H Wagener, Z Weiszhart, C E Wheelock, S J Wilson

Affiliations

¹ University of Manchester, and Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
² Department of Sport, Health and Exercise Science, School of Life Sciences, The University of Hull, Hull, UK.
³ Respiratory Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
⁴ Respiratory Research Unit, University of Nottingham, Nottingham, UK.
⁵ National Heart and Lung Institute, Imperial College, London, UK.
⁶ Royal Brompton and Harefield NHS Trust, London, UK.
⁷ NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK.
⁸ Respiratory Therapeutic Unit, GSK, London, UK.
⁹ Acclarogen Ltd, St John's Innovation Centre, Cambridge, UK.
¹⁰ Data Science Institute, Imperial College, London, UK.
¹¹ Department of Clinical Science, University of Bergen, Bergen, Norway.
¹² Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
¹³ Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.
¹⁴ Department of Pulmonology, Semmelweis University, Budapest, Hungary.
¹⁵ Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
¹⁶ Università Cattolica del Sacro Cuore, Milan, Italy.
¹⁷ Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
¹⁸ Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
¹⁹ BioSci Consulting, Maasmechelen, Belgium.

PMID: 30307629
PMCID: PMC6587719
DOI: 10.1111/all.13629

No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr Simpson has nothing to disclose; Dr. Hekking has nothing to disclose; Dr Shaw reports advisory board fees from GSK, Novartis and AZ and travel fees from TEVA and AZ; Dr. Fleming reports personal fees from Vectura, personal fees from Novartis, personal fees from Boehringer Ingelheim, outside the submitted work; Dr. Roberts reports grants to University of Southampton during the conduct of the study; Dr. Riley reports he is employed by and holds shares in GlaxoSmithKline. Dr. Bates reports he is employed by and holds shares in GlaxoSmithKline. Dr. Sousa has nothing to disclose. Dr. Bansal has nothing to disclose. Dr. Pandis has nothing to disclose. Dr. Sun has nothing to disclose. Dr P Bakke has nothing to disclose. Dr. Caruso has nothing to disclose. Dr. B Dahlén reports personal fees from Advisory Board membership, personal fees from Payments for lectures, outside the submitted work; Dr. S‐E Dahlén reports personal fees from AZ, GSK, Merck, Novartis, RSPR AB, Teva, outside the submitted work; Dr. Horvath reports personal fees from AstraZeneca, Boehringer‐Ingelheim, GSK, Novartis, CSL Behring, Roche, Sandoz, Chiesi, Sager Pharma, Orion, Affidea and Teva, outside the submitted work. Dr. Krug reports grants from IMI, during the conduct of the study; Dr. Montuschi reports personal fees from AstraZeneca, outside the submitted work; Dr. Sandstrom reports personal fees from AstraZeneca, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from Novartin, personal fees from Teva, outside the submitted work; Dr. Singer has nothing to disclose; Dr. Adcock reports grants from EU‐IMI, during the conduct of the study; Dr. Wagers reports grants from Innovative Medicines Initiative, other from Roche, grants from European respiratory society, during the conduct of the study, other from GSK, other from European Respiratory Society, outside the submitted work; Dr. Chung reports personal fees from Advisory Board membership, grants for research, personal fees from payments for lectures, outside the submitted work; Dr. Sterk reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study; Dr. Fowler has nothing to disclose.

The research leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking, under grant agreement no. 115010, resources for which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007‐2013) and kind contributions from companies in the European Federation of Pharmaceutical Industries and Associations (EFPIA) (www.imi.europa.eu).

Cited by

Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma.
Kim BK, Park SY, Ban GY, Kim MA, Lee JH, An J, Shim JS, Lee Y, Won HK, Lee HY, Sohn KH, Kang SY, Park SY, Lee H, Kim MH, Kwon JW, Yoon SY, Lee JH, Rhee CK, Moon JY, Lee T, Kim SR, Park JS, Kim SH, Park HW, Jeong JW, Kim SH, Koh YI, Oh YM, Jang AS, Yoo KH, Cho YS; Korean Academy of Asthma, Allergy, and Clinical Immunology (KAACI), the Working Group on Severe Asthma. Kim BK, et al. Allergy Asthma Immunol Res. 2020 Nov;12(6):910-933. doi: 10.4168/aair.2020.12.6.910. Allergy Asthma Immunol Res. 2020. PMID: 32935486 Free PMC article. Review.
Management of severe asthma: from stepwise approach to therapy to treatable traits?
Wang G, McDonald VM, Gibson PG. Wang G, et al. Precis Clin Med. 2021 Dec 3;4(4):293-296. doi: 10.1093/pcmedi/pbab028. eCollection 2021 Dec. Precis Clin Med. 2021. PMID: 35692859 Free PMC article. No abstract available.
Influence of sex, cigarette smoking and airway inflammation on treatable traits in CBIOPRED severe asthma.
Dong C, Yang X, Luo W, Fan E, Assam NP, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Fu X, Wang C, Shen H, Jin M, Zhu L, Shi G, Qiu Z, Wen Z, Gu W, Chung KF, Zhang Q, Zhong N; C‒BIOPRED consortium. Dong C, et al. Clin Transl Allergy. 2022 Sep 15;12(9):e12189. doi: 10.1002/clt2.12189. eCollection 2022 Sep. Clin Transl Allergy. 2022. PMID: 36176735 Free PMC article. No abstract available.
Multimorbidity in Difficult Asthma: The Need for Personalised and Non-Pharmacological Approaches to Address a Difficult Breathing Syndrome.
Varkonyi-Sepp J, Freeman A, Ainsworth B, Kadalayil LP, Haitchi HM, Kurukulaaratchy RJ. Varkonyi-Sepp J, et al. J Pers Med. 2022 Aug 31;12(9):1435. doi: 10.3390/jpm12091435. J Pers Med. 2022. PMID: 36143220 Free PMC article. Review.
Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.
Breiteneder H, Peng YQ, Agache I, Diamant Z, Eiwegger T, Fokkens WJ, Traidl-Hoffmann C, Nadeau K, O'Hehir RE, O'Mahony L, Pfaar O, Torres MJ, Wang DY, Zhang L, Akdis CA. Breiteneder H, et al. Allergy. 2020 Dec;75(12):3039-3068. doi: 10.1111/all.14582. Epub 2020 Sep 30. Allergy. 2020. PMID: 32893900 Free PMC article. Review.

See all "Cited by" articles

References

1. Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993‐2012). Lancet. 2017;390:935‐945. - PubMed
1. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410‐419. - PubMed
1. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U‐BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308‐1321. - PubMed
1. Lefaudeux D, De Meulder B, Loza MJ, et al. U‐BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139:1797‐1807. - PubMed
1. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391:350‐400. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatable traits in the European U-BIOPRED adult asthma cohorts

Collaborators

Affiliations

Treatable traits in the European U-BIOPRED adult asthma cohorts

Authors

Collaborators

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical